Pivotal bioVenture Partners China (Pivotal China), a member of Nan Fung Life Sciences announced the closing of Pivotal bioVenture Partners China USD Fund I, raising US$150 million to incubate and build life sciences companies in China. Pivotal China will focus on in-licensing innovative products and technologies of target companies that could serve unmet medical needs of the growing China market. Pivotal China will invest broadly in pharmaceuticals, devices and service sectors, the company said. "China is catching up in healthcare …

HK Conglomerate Nan Fung Group’s Pivotal China Closes $150M USD Fund appeared first on China Money Network.


Visit the original source and full text: China Money Network